TJP1 and Miyoshi myopathy: Our in vitro findings were supported by an independent clinical data set [21] where MM patients with the LP-1/Cfz-like molecular phenotype — i.e, high TJP1, WWTR1/TAZ and TEAD1 expression — was associated with inferior overall survival outcomes.